The announcement that CVC Capital Partners has reached an agreement to acquire Animal Nutrition & Health (ANH)from DSM-Firmenich at an enterprise value of approximately €2.2bn, including an earn-out of up to €0.5bn, was received by the market as a major transaction. DSM-Firmenich will retain a 20% equity stake in the divested businesses, while the transaction is expected to close toward the end of 2026, subject to approvals.
At the headline level, this looks like a classic private equity carve-out. A diversified group sharpening focus, and a financial sponsor stepping in to unlock operational and financial upside. But that reading misses the deeper signal. This deal is not primarily about ownership. It is about how animal nutrition itself is being structurally redefined.
As part of the transaction, ANH will be split into two standalone companies, both headquartered in Kaiseraugst, Switzerland. One will operate as a Solutions Company, covering Performance Solutions, Premix and Precision Services. The other will operate as an Essential Products Company, focused on Vitamins, Carotenoids and Aroma Ingredients. The two entities will remain commercially connected, particularly around vitamin supply, but they will follow distinct operating and investment logics.
This split formalises something the sector has been grappling with for more than a decade. Animal nutrition is no longer a single business model. It is at least two, with different economics, capital needs, and paths to value creation.
The Essential Products business behaves like an industrial platform. Its performance is driven by scale, manufacturing efficiency, procurement power, energy exposure and working capital discipline. Margins are cyclical and sensitive to global supply chains, but resilience comes from footprint, reliability and cost control.
The Solutions business, by contrast, behaves more like a proximity and knowledge platform. Its value proposition depends on formulation expertise, advisory services, data interpretation and the ability to translate biology into measurable performance outcomes under real-world farm constraints. Growth is not primarily a function of volume, but of penetration into decision-making at farm and integrator level.
By separating these models, the transaction does something very specific: it makes them priceable on different terms. Private equity does not buy narratives; it buys cash-flow profiles and exit optionality. Two businesses mean two potential equity stories, two capital structures and, eventually, two different exit routes.
From CVC’s perspective, the attraction is clear. ANH generated annualised net sales of around €3.5bn in 2025 and employs approximately 8,000 people globally. This scale enables meaningful operational re-engineering. The financial architecture of the deal itself reinforces that point. DSM-Firmenich expects to receive approximately €1.2bn at closing, composed of net cash proceeds, debt and liability transfers, and a vendor loan note. In parallel, it will provide the Essential Products Company with a loan facility of up to €450m and a potential liquidity backstop of up to €115m, both to be redeemed at exit.
This is a staged separation, designed to preserve continuity, de-risk Day-1 operations and allow value to be built methodically before exit. That staging matters because it reveals where power and optionality really sit in the early years of the carve-out.
For those closer to livestock production, however, the strategic split raises a more uncomfortable question. If animal nutrition is moving decisively toward “solutions”, precision services and integrated health narratives, who actually captures the resulting efficiency gains?
Private equity entering animal nutrition at this scale signals confidence in long-term margins. But it also implies faster consolidation, tighter coupling of nutrition with health monitoring, and premium pricing strategies justified by “precision”, “ROI” and “outcome-based” language. In theory, this should benefit producers through better performance and lower variability. In practice, the transmission mechanism is far from guaranteed.
In fragmented production regions, such as much of the Mediterranean basin, farm structures are heterogeneous, data availability is uneven and advisory capacity is often limited. In my experience in Greece, the gap between what technology promises at the corporate level and what it delivers at the stable level remains significant. Precision systems tend to work best where decision loops are tight, scale is sufficient, and implementation discipline is high. When those conditions are absent, value tends to be re-priced upstream rather than shared downstream.
This is where the mechanics of the carve-out become more important than the strategy itself. Large separations rarely fail because of flawed strategic logic. They succeed or fail because of how stand-alone economics are constructed.
Carve-out experience shows that the real battleground lies in the transition from reported EBITDA to true stand-alone EBITDA. Shared resources, group charges, IT platforms, procurement structures and central functions must be disentangled. Transition Service Agreements determine continuity, cost allocation and, ultimately, negotiating leverage. New stand-alone costs emerge precisely in the areas that “solutions” businesses depend on most: data systems, analytics, advisory infrastructure and commercial enablement.
In the ANH case, this tension is particularly acute. The Essential Products Company will inherit capital-intensive assets and supply-chain exposure. The Solutions Company will inherit complexity, requiring investment in capabilities that were previously embedded in a larger group. The apparent margin profiles of the two entities will therefore depend less on science and more on how TSAs are designed, priced and exited.
This is why TSAs are not a technical footnote. They are the real axis of control in the first phase after closing. The fact that dsm-firmenich will remain a key vitamin supplier, provide liquidity support and retain a 20% equity stake strongly suggests that independence will be gradual rather than immediate. Pricing power, cost discipline and customer relationships will evolve over time, not overnight.
The retained equity stake itself deserves careful interpretation. It is tempting to read it purely as an upside play: a signal that dsm-firmenich believes ANH’s value will grow under focused ownership. That is likely true. But rolling equity also functions as a risk hedge. Carve-outs create value for the divested entity, but they also generate stranded costs and adjustment pressure for the remaining business. Retaining exposure allows the seller to participate in future value creation while partially offsetting near-term disruption.
One further boundary in the transaction clarifies the long-term direction of travel. High-profile platforms such as Bovaer® and Veramaris™ remain with dsm-firmenich. This is not accidental. It signals that climate-linked, highly differentiated innovation sits in a different strategic category from the broader ANH portfolio. The result is a sector increasingly owned by different types of capital, each with distinct time horizons and return expectations.
For producers, the implications are concrete. As solutions become more bundled and more expensive, farms have only a limited set of viable responses. Decision infrastructure must improve, even if technology adoption remains modest. Performance claims must be challenged with outcome-based logic rather than accepted as product narratives. And collective structures, whether cooperatives or producer groups, become more important, not less, in a world where global suppliers monetise integration and service layers.
The CVC–dsm-firmenich ANH deal is therefore not just a transaction. It is a case study in how value in animal agriculture is being reorganised. Less around molecules, more around operating models. Less around volume, more around decision control. And increasingly, less around who produces the animal, and more around who defines how production decisions are made.
That is why this carve-out deserves attention well beyond the M&A headlines.
